# Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer

> **NCT04182568** · PHASE4 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel followed by anthracycline and cyclophosphamide
- **DRUG:** Docetaxel followed by anthracycline and cyclophosphamide

## Key facts

- **NCT ID:** NCT04182568
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-21
- **Primary completion:** 2021-08-21
- **Final completion:** 2022-08-21
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182568, "Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04182568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*